MARKET

TLPH

TLPH

Talphera Inc
NASDAQ
0.7458
+0.0043
+0.58%
After Hours: 0.7458 0 0.00% 16:10 03/30 EDT
OPEN
0.7612
PREV CLOSE
0.7415
HIGH
0.7612
LOW
0.7122
VOLUME
131.21K
TURNOVER
--
52 WEEK HIGH
1.570
52 WEEK LOW
0.3800
MARKET CAP
37.33M
P/E (TTM)
-2.2137
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TLPH last week (0323-0327)?
Weekly Report · 17h ago
Talphera CEO Vincent J. Angotti acquires 213,310 common shares; value rises to $125,000
Reuters · 5d ago
Talphera announces two abstracts accepted for AKI & CRRT 2026; NEPHRO-CRRT nafamostat registrational study enrolls patients
Reuters · 5d ago
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
PR Newswire · 5d ago
Talphera files to sell 639,931 shares of common stock for holders
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Talphera (TLPH) and Abivax SA Sponsored ADR (ABVX)
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Compass Therapeutics (CMPX) and Talphera (TLPH)
TipRanks · 6d ago
Midday Fly By: Musk to start Terafab project, Elliott takes stake in Synopsys
TipRanks · 03/23 16:06
More
About TLPH
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Webull offers Talphera Inc stock information, including NASDAQ: TLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLPH stock methods without spending real money on the virtual paper trading platform.